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Adrian Goodey is a Principal Scientist in the Specialty Dosage
Forms group within Merck Research Laboratories. In this role,
Dr. Goodey leads the development of drug products delivered
via alternate routes of administration, including inhalers,
nasal sprays and subcutaneous implants. His research
interests include advancing the science of aerodynamic
particle sizing and the development of clinically relevant
analytical methods for pharmaceutical testing. To date, he
has authored fourteen peer-reviewed scientific articles and
two patents.
Complications related to pregnancy and child birth claim nearly 800 women’s lives each day. This tragedy is 
compounded by the fact that the vast majority of these deaths are preventable. However, ninety-nine 
percent of maternal deaths occur in the developing world where basic medical services and supplies are 
typically scarce. Postpartum hemorrhage (PPH; excessive bleeding after child birth), accounts for nearly 25% 
of maternal deaths globally, and is an especially acute concern in resource-scarce settings. The 
pharmacological treatment recommended for PPH by the World Health Organization, oxytocin, is 
incompatible with regions where reliable refrigeration is unavailable. Typically formulated as an aqueous 
solution for injection, oxytocin rapidly loses efficacy at room temperature via chemical degradation.
In the present work, we explore the feasibility of adapting oxytocin from its standard injectable solution form 
to a dry powder formulation for intranasal administration. A preclinical evaluation reveals an impressive 12% 
bioavailability (relative to intramuscular injection) with sufficiently rapid onset for treatment of PPH. 
Moreover, in-vitro characterization confirmed good physical and chemical stability, offering hope that dry 
powder oxytocin formulations for intranasal delivery may be a viable option for treatment of PPH in the 
developing world.
